Dr Frank Pun serves as the Head of Insilico Hong Kong at Insilico Medicine, a pioneering global biotechnology company dedicated to integrating AI and automation technologies to accelerate drug discovery. He leads a team of R&D and application scientists focusing on AI-powered biological target discovery, indication expansion, drug repurposing, and AI biomedical platform development. His team has recently introduced TargetPro, a disease-specific machine learning model for therapeutic target discovery, as well as PandaOmics Agent (for biological science) and inClinico Agent (for clinical science) to biomedical professionals worldwide, empowering them to accelerate drug discovery and development.

Dr Frank Pun received his Ph.D. in Biochemistry from the Hong Kong University of Science and Technology in 2010. Following his graduation, he served as a visiting scholar and led a team dedicated to studying human central nervous system diseases and cancer for several years. In 2019, he obtained an MBA from Rutgers Business School in the United States. Throughout his career, Dr. Pun has made significant contributions to the fields of target discovery, drug repurposing, and AI-powered biomedical platform development. His work has appeared in numerous industry collaborations and peer-reviewed publications.

Dr Charleston Sin is a veteran technology leader currently serving as the Executive Director of mComo, an AI application firm, a Co-founder of Peach Bioverse, a health data startup, and Co-founder of Kapok Capital, a deep tech investment firm, with focus on digital health.

Dr Sin was Executive Director of MIT Hong Kong Innovation Node.  Prior to joining MIT, Dr Sin held executive positions in research and development, product management, and sales & marketing at VMware, Cisco Systems, and Nortel Networks in the United States, Canada, Asia Pacific, and Greater China for 25 years.
 
He is Professor of Practice in the Faculty of Business at the Hong Kong Polytechnic University and Adjunct Full Professor of Department of Electric and Electronic Engineering of the Hong Kong University.
 
Dr Sin spends time to serve digital health community. He is the President of Hong Kong eHealth Consortium; a co-op member of Information Technology Services Committee (ITSC) of Hong Kong Hospital Authority; and a member of the Steering Committee on eHealth of Health Bureau, HK SAR.

Dr Sin studied Innovation Management and received his PhD in Management Sciences at Faculty of Engineering, the University of Waterloo in Canada in 1998. 

Ms Pauli Wong is Principal and Chinese Patent Attorney at Eagle IP, a top-tier patent specialist firm based in Hong Kong. Pauli has been with Eagle IP for over 11 years, overseeing the drafting team, helping local and international clients with patent drafting and prosecution in a wide range of technology areas including biotechnology, medical devices, robotics, biology, and more, and advising them on IP rights, portfolio management, and global filing strategy. Before jumping into the patent world, Pauli has gained rich portfolio of technical experience in R&D, method development, and validation in the areas of microbiology, molecular biology, proteomics, and chemistry from her previous positions at CK Life Sciences Limited. Pauli holds an MPhil degree in Molecular Microbiology and a BSc degree in Animal and Plant Biotechnology both from HKU. Pauli loves working with Hong Kong innovators to build up good IP portfolios that meet their business needs. She has proven herself to be a fast learner of new technologies, conscientious in patent prosecution, strategic in the way she works with businesses, and generous in how she takes care of her clients. She actively promotes awareness of patent protection within our local community, actively supports and advises on the legislative development of the regulatory standards for patent agents, gives IP talks at various events and guide the next generation towards the patent law career.

Dr Wilson Wong is a healthcare-focused entrepreneur with a PhD, MPhil, and BEng from the University of Hong Kong, specializing in biomechanics, biomaterials, and bone-related diseases. He also completed technopreneurship training at IECT, University of Cambridge, supported by Dr Hermann Hauser. In 2014, he founded NOVUS Life Sciences Limited, where he currently serves as Chairman and CEO. NOVUS, a global leader in 3D printing biomaterials, operates cutting-edge manufacturing facilities in Hong Kong and Shenzhen. The company supplies to 50+ countries and 150+ corporate clients, supporting the production of patient-specific implants and devices.

Wilson is actively engaged in the startup ecosystem and dedicated to fostering entrepreneurship education. He has been a featured speaker and lecturer at institutions and Bloomberg. Under his leadership, NOVUS has received numerous prestigious awards, including Champion of IMAGINE IF!, CNBC’s hottest startups, and accolades from GIN Austria, French Tech Ticket, and Alibaba Jumpstarter.

Mr Tony Yung is Chief Commercial Officer of the Advanced Biomedical Instrumentation Centre, an innovative research and biomedical entrepreneurship centre of the University of Hong Kong. He is an industry expert in healthcare, med-tech, digital health & AI. He focused on business development, complex project management and new invention commercialization. He has built and managed six start-ups across the fields of disease screening, diagnostics, medical data science, artificial intelligence, and agriculture. He received his early training in biotechnology in CUHK and Prince of Wales Hospital, Hong Kong, and he subsequently worked as a technology strategy consultant in the Global Business Services division of IBM. In the last decade, he has worked with many innovation-driven companies and scientific leaders in Hong Kong, US and Mainland China to build and run exciting businesses and execute major commercial deals. He also serves as Board member in NGOs including the eHealth Consortium and the Greater Bay Area Youth Development Association. He is a Fellow of the Hong Kong College of Health Service Executives and Australasian College of Health Service Management.